Consistent with an important role in tumor initiation, seminal epidemiological studies of the COX-2 inhibitor Celecoxib demonstrated striking benefits in colorectal cancer prevention, but at the risk of increased thrombosis and cardiovascular events, leading to the discontinuation of cancer prevention studies (7, 8). This evidence concerns the gene PTGS2 and cancer.